Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited (BRIBY) delivers innovative therapies targeting chronic hepatitis B and infectious diseases through advanced biotherapeutic platforms. This news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory progress.
Access authoritative reporting on key initiatives including HBV combination therapies, siRNA advancements, and global clinical trial updates. Our curated news collection ensures you stay informed about BRII-877, BRII-835, and other pipeline candidates without promotional bias.
Discover verified updates across essential categories: clinical trial results, regulatory submissions, research collaborations, and therapy development milestones. Each update is vetted for relevance to long-term therapeutic goals and shareholder value.
Bookmark this page for streamlined access to Brii Biosciences' latest advancements in functional cure research. Check regularly for objective reporting on innovations shaping the future of HBV treatment.
Brii Biosciences (BRIBY) has entered into a licensing agreement with Joincare Group for the exclusive rights to develop and commercialize BRII-693 in Greater China. BRII-693 is a novel synthetic lipopeptide designed to treat critically ill patients with multidrug-resistant gram-negative bacterial infections.
Under the agreement, Joincare will take full responsibility for development, regulatory approval, and commercialization in Greater China. Brii Bio will receive an upfront payment, milestone payments, and tiered royalties on net sales. The drug has shown promising results in Phase 1 studies, demonstrating favorable safety and tolerability profiles in both Chinese and non-Chinese participants.
The drug specifically targets infections caused by carbapenem-resistant bacteria, including Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacterales (CRE). BRII-693 has already received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China.
Brii Bio (BRIBY) has unveiled new data from its ongoing Phase 2 ENSURE study at APASL 2025, highlighting promising results in treating chronic HBV infection. The study's Cohort 4 data revealed that participants who previously responded to BRII-179 (therapeutic vaccine) achieved a 55.6% HBsAg seroclearance rate at Week 24, compared to only 10% in non-responders.
The 48-week data from Cohorts 1-3 demonstrated that the combination of elebsiran (siRNA) with PEG-IFNα achieved higher HBsAg loss rates of 26.3% (200mg) and 33.3% (100mg), significantly outperforming PEG-IFNα alone (5.6%). The combination therapy showed greater HBsAg reductions and was generally well-tolerated.
This data supports BRII-179's potential as a predictive tool for identifying patients more likely to respond to curative therapies, potentially improving treatment efficiency for the 254 million patients worldwide living with chronic HBV infection.
Brii Biosciences (BRIBY) has provided its full-year 2024 financial results and corporate update, highlighting significant progress in its hepatitis B virus (HBV) functional cure program. The company reported strong cash reserves of US$335.7 million, sufficient to fund operations into 2028.
Key developments include the strategic acquisition of BRII-179's intellectual property for $18 million and advancement of multiple Phase 2b studies. The ENHANCE study completed enrollment in January 2025, while the ENSURE study showed promising 48-week end-of-treatment data, demonstrating higher HBV surface antigen loss rates with elebsiran combination therapy.
Financial results showed a cash position of RMB2,413.4 million, down 9.3% year-over-year. Research and development expenses decreased by 38% to RMB249.8 million, while administrative expenses reduced by 22% to RMB153.2 million. The company reported an increased loss of RMB512.4 million for 2024, up 177.9% from 2023, primarily due to investment-related losses and impairment charges.
Brii Bio (2137.HK) has signed asset purchase agreements to acquire full intellectual property rights and assets related to BRII-179 from VBI Vaccines for US$18 million. This acquisition eliminates future milestone and royalty obligations to VBI and secures uninterrupted clinical supply of BRII-179. The company will also terminate previous agreements with VBI from February 14, 2024, canceling all payment obligations except for a US$2.5 million promissory note.
The company has initiated several BRII-179-containing combination studies targeting higher functional cure rates for chronic Hepatitis B Virus (HBV) infection. Notably, patient enrollment has been completed for the ENRICH study, a Phase 2b trial evaluating sequential treatment of BRII-179 followed by elebsiran and PEG-IFNα combination.
Brii Bio announced new data from its Phase 2 ENSURE study, comparing elebsiran (BRII-835) combined with PEG-IFNα versus PEG-IFNα alone in chronic HBV patients. The 48-week end-of-treatment results showed significantly higher HBsAg seroclearance rates in combination therapy groups: 26.3% (200mg elebsiran) and 33.3% (100mg elebsiran) versus 5.6% with PEG-IFNα alone. In patients with baseline HBsAg of 100-1,500 IU/mL, the combination achieved even higher rates: 31.3% (200mg) and 40.0% (100mg). The combination therapy demonstrated greater HBsAg reductions and was generally safe and well-tolerated.
Brii Bio presented new data from its ongoing Phase 2 trials at the EASL Congress 2024. The data revealed that BRII-179, a therapeutic vaccine, induced significant immune responses and high levels of HBsAg reduction in some participants with chronic HBV infection.
The trials evaluated BRII-179 either in combination with BRII-835 (elebsiran) or as an add-on to PEG-IFNa treatment. Findings included increased B and T cell responses, enhanced HBsAg loss post-treatment, and no need for NRTI retreatment.
The combination therapies were safe and well tolerated, supporting further evaluation for achieving a functional cure for chronic HBV infection.
Brii Biosciences announced that the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for two of its investigational therapies: BRII-877 (tobevibart) and BRII-835 (elebsiran). These therapies target hepatitis B virus (HBV) and are supported by extensive Phase 1 and 2 studies. BRII-877 has treated over 350 patients, showing well-tolerated results and significant decreases in HBsAg levels. BRII-835, studied in over 570 patients, demonstrated robust antiviral activity against HBV. These designations bolster Brii Bio’s ongoing efforts to develop functional cures for chronic HBV and HDV infections, enhancing their therapeutic regimens to achieve higher cure rates in broader patient populations.
